Ovid Therapeutics Inc (OVID)

$2.90 +0.06 (2.11%)
Market Cap 564.41M
Revenue (ttm) 7.25M
Net Income (ttm) -17.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -240.14%
Debt to Equity Ratio 0.00
Volume 1,085,062
Avg Vol 2,483,056
Day's Range N/A - N/A
Shares Out 195.30M
Stochastic %K 84%
Beta 0.21
Analysts Strong Sell
Price Target $5.38

Company Profile

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the tr...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 661 7661
Fax: 646 661 4027
Address:
Hudson Commons, 441 9th Avenue 14th Floor, New York, United States
Dubbyy
Dubbyy Aug. 17 at 3:49 PM
$OVID Check out this article from TipRanks | Ovid Therapeutics: Buy Rating on Advancing OV329 Seizure Pipeline and Strong Cash Runway Through 2029 | https://tipranks.onelink.me/WJho/jpg3t97m
0 · Reply
LSOTradingDesk
LSOTradingDesk Aug. 15 at 9:16 PM
$OVID 👀
0 · Reply
Dubbyy
Dubbyy Aug. 14 at 2:59 PM
$OVID Check out this article from TipRanks | Reiterated Buy Rating on Ovid Therapeutics as Solid Pipeline Execution and Two-Year Cash Runway Support Unchanged $5 Price Target | https://tipranks.onelink.me/WJho/3eekpcxi
0 · Reply
Dubbyy
Dubbyy Aug. 13 at 8:10 PM
$OVID https://tipranks.onelink.me/WJho/8178p2wk
0 · Reply
lucabrix
lucabrix Aug. 13 at 8:10 PM
$OVID here we go again!
0 · Reply
focafoca99
focafoca99 Aug. 13 at 1:09 PM
$OVID issued a press release with Q2 2026 results and business updates.
0 · Reply
d_risk
d_risk Aug. 13 at 12:39 PM
$OVID - Ovid Therapeutics Inc - 10Q - Updated Risk Factors 🚨 Peer Alert: Risk-factor words are +136.6% above peer average (27,850 vs 11,769 across 655 peers). Ovid flags new risks from U.S. drug importation programs and expanding use of social media and generative AI/AI-based tools, which could trigger compliance issues, data/privacy leaks, IP loss, reputational damage and financial reporting control failures. #Biotechnology #Pharmaceuticals #DrugImportationRisks #AICompliance #DataPrivacy 🟢 Added 🟠 Removed https://d-risk.ai/OVID/10-Q/2026-08-13
0 · Reply
michaelhearn
michaelhearn Aug. 13 at 1:37 AM
$OVID 81% bought!
0 · Reply
lucabrix
lucabrix Aug. 4 at 7:46 PM
$OVID Reply!
0 · Reply
michaelhearn
michaelhearn Aug. 4 at 4:28 PM
$OVID waking up with rest of market. Raised target of $9
0 · Reply
Latest News on OVID
Ovid Therapeutics reports Q2 EPS (8c), consensus (10c)

2026-08-17T07:43:18.000Z - 2 days ago

Ovid Therapeutics reports Q2 EPS (8c), consensus (10c)

Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results

Aug 13, 2026, 8:30 AM EDT - 6 days ago

Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results

Ovid Therapeutics Slides: Corporate presentation

Aug 13, 2026, 8:00 AM EDT - 6 days ago

Ovid Therapeutics Slides: Corporate presentation

Ovid Therapeutics Quarterly report: Q2 2026

Aug 13, 2026, 7:00 AM EDT - 6 days ago

Ovid Therapeutics Quarterly report: Q2 2026

Ovid Therapeutics Earnings release: Q2 2026

Aug 13, 2026, 7:00 AM EDT - 6 days ago

Ovid Therapeutics Earnings release: Q2 2026

Ovid Therapeutics price target raised to $9 from $7 at Oppenheimer

2026-08-03T12:11:28.000Z - 16 days ago

Ovid Therapeutics price target raised to $9 from $7 at Oppenheimer

Ovid Therapeutics CFO Jeffrey Rona to step down, Charles Carter to succeed

2026-07-08T11:25:10.000Z - 6 weeks ago

Ovid Therapeutics CFO Jeffrey Rona to step down, Charles Carter to succeed

Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development

Jul 8, 2026, 7:00 AM EDT - 6 weeks ago

Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development

Ovid Therapeutics Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference

Jun 15, 2026, 7:00 AM EDT - 2 months ago

Ovid Therapeutics Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference

Ovid Therapeutics Transcript: AGM 2026

Jun 10, 2026, 10:30 AM EDT - 2 months ago

Ovid Therapeutics Transcript: AGM 2026

Ovid Therapeutics to Participate in Upcoming Investor Conferences

Jun 4, 2026, 7:00 AM EDT - 2 months ago

Ovid Therapeutics to Participate in Upcoming Investor Conferences

Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors

Jun 3, 2026, 7:00 AM EDT - 2 months ago

Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors

Ovid Therapeutics price target raised to $7 from $5 at Roth Capital

2026-05-14T14:49:13.000Z - 3 months ago

Ovid Therapeutics price target raised to $7 from $5 at Roth Capital

Ovid Therapeutics reports Q1 EPS (12c), consensus (11c)

2026-05-12T12:02:41.000Z - 3 months ago

Ovid Therapeutics reports Q1 EPS (12c), consensus (11c)

Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

May 12, 2026, 7:00 AM EDT - 3 months ago

Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

Ovid Therapeutics Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 3 months ago

Ovid Therapeutics Quarterly report: Q1 2026

Ovid Therapeutics Earnings release: Q1 2026

May 12, 2026, 7:00 AM EDT - 3 months ago

Ovid Therapeutics Earnings release: Q1 2026

Ovid Therapeutics Slides: Corporate presentation

May 12, 2026, 7:00 AM EDT - 3 months ago

Ovid Therapeutics Slides: Corporate presentation

Ovid Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Ovid Therapeutics Proxy statement: Proxy filing

Ovid Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Ovid Therapeutics Proxy statement: Proxy filing

Ovid Therapeutics files to sell 29.86M shares of common stock for holders

2026-04-21T20:36:47.000Z - 4 months ago

Ovid Therapeutics files to sell 29.86M shares of common stock for holders

Ovid Therapeutics Registration statement: Registration filing

Apr 21, 2026, 8:00 AM EDT - 4 months ago

Ovid Therapeutics Registration statement: Registration filing

Ovid Therapeutics Transcript: Status update

Apr 14, 2026, 9:30 AM EDT - 4 months ago

Ovid Therapeutics Transcript: Status update

Ovid Therapeutics Slides: Status update

Apr 14, 2026, 9:30 AM EDT - 4 months ago

Ovid Therapeutics Slides: Status update

Ovid Therapeutics price target raised to $4 from $2 at H.C. Wainwright

2026-04-09T10:10:35.000Z - 4 months ago

Ovid Therapeutics price target raised to $4 from $2 at H.C. Wainwright

Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14

Apr 8, 2026, 8:00 AM EDT - 4 months ago

Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14

Ovid Therapeutics price target raised to $7 from $5 at Wedbush

2026-03-20T12:01:46.000Z - 5 months ago

Ovid Therapeutics price target raised to $7 from $5 at Wedbush

Ovid Therapeutics price target raised to $5 from $3 at Roth Capital

2026-03-19T14:25:25.000Z - 5 months ago

Ovid Therapeutics price target raised to $5 from $3 at Roth Capital

Ovid Therapeutics Earnings Call Transcript: Q4 2025

Mar 18, 2026, 8:30 AM EDT - 5 months ago

Ovid Therapeutics Earnings Call Transcript: Q4 2025

Ovid Therapeutics Annual report: Q4 2025

Mar 18, 2026, 8:30 AM EDT - 5 months ago

Ovid Therapeutics Annual report: Q4 2025

Ovid Therapeutics Earnings release: Q4 2025

Mar 18, 2026, 8:30 AM EDT - 5 months ago

Ovid Therapeutics Earnings release: Q4 2025

Ovid Therapeutics Slides: Q4 2025

Mar 18, 2026, 8:30 AM EDT - 5 months ago

Ovid Therapeutics Slides: Q4 2025

Ovid Therapeutics announces Phase 1 clearance for OV4071

2026-03-18T10:16:18.000Z - 5 months ago

Ovid Therapeutics announces Phase 1 clearance for OV4071

Ovid Therapeutics reports Q4 EPS 6c, consensus (10c)

2026-03-18T10:15:47.000Z - 5 months ago

Ovid Therapeutics reports Q4 EPS 6c, consensus (10c)

Ovid Therapeutics sees cash runway into late 2028

2026-03-18T10:15:34.000Z - 5 months ago

Ovid Therapeutics sees cash runway into late 2028

Ovid Therapeutics announces OV239 data, indication expansion

2026-03-18T10:10:52.000Z - 5 months ago

Ovid Therapeutics announces OV239 data, indication expansion

Ovid Therapeutics prices 19.15M shares at $2.01 in private placement

2026-03-18T10:06:08.000Z - 5 months ago

Ovid Therapeutics prices 19.15M shares at $2.01 in private placement

Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 18, 2026, 6:05 AM EDT - 5 months ago

Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results

Ovid Therapeutics Announces Pricing of $60 Million Private Placement

Mar 18, 2026, 6:00 AM EDT - 5 months ago

Ovid Therapeutics Announces Pricing of $60 Million Private Placement

Ovid Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 11, 2026, 3:00 PM EDT - 5 months ago

Ovid Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Ovid Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 9:50 AM EST - 6 months ago

Ovid Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Ovid Therapeutics initiated with an Outperform at LifeSci Capital

2025-12-22T12:50:56.000Z - 8 months ago

Ovid Therapeutics initiated with an Outperform at LifeSci Capital

Ovid Therapeutics reports Phase 1 results for KCC2, OV350 IV

2025-12-18T13:05:15.000Z - 8 months ago

Ovid Therapeutics reports Phase 1 results for KCC2, OV350 IV

Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)

Dec 18, 2025, 8:00 AM EST - 8 months ago

Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)

Ovid Therapeutics files to sell 125.06M shares of common stock for holders

2025-12-15T22:30:46.000Z - 8 months ago

Ovid Therapeutics files to sell 125.06M shares of common stock for holders

Ovid Therapeutics Registration statement: Registration Filing

Dec 15, 2025, 7:00 AM EST - 8 months ago

Ovid Therapeutics Registration statement: Registration Filing

Ovid Therapeutics initiated with a Buy at Roth Capital

2025-12-11T10:15:12.000Z - 8 months ago

Ovid Therapeutics initiated with a Buy at Roth Capital

Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer

Dec 2, 2025, 7:00 AM EST - 9 months ago

Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer

Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results

Nov 12, 2025, 7:00 AM EST - 10 months ago

Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results

Ovid Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 2:00 AM EST - 10 months ago

Ovid Therapeutics Earnings release: Q3 2025

Ovid Therapeutics Quarterly report: Q3 2025

Nov 12, 2025, 2:00 AM EST - 10 months ago

Ovid Therapeutics Quarterly report: Q3 2025

Ovid Therapeutics Proxy statement: Proxy Filing

Nov 7, 2025, 7:00 AM EST - 10 months ago

Ovid Therapeutics Proxy statement: Proxy Filing

Ovid Therapeutics Proxy statement: Proxy Filing

Oct 28, 2025, 8:00 AM EDT - 10 months ago

Ovid Therapeutics Proxy statement: Proxy Filing

Ovid Therapeutics Proxy statement: Proxy Filing

Oct 27, 2025, 8:00 AM EDT - 10 months ago

Ovid Therapeutics Proxy statement: Proxy Filing

Ovid Therapeutics Transcript: Study Result

Oct 3, 2025, 8:30 AM EDT - 11 months ago

Ovid Therapeutics Transcript: Study Result

Ovid Therapeutics Press release: Study Result

Oct 3, 2025, 8:30 AM EDT - 11 months ago

Ovid Therapeutics Press release: Study Result

Ovid Therapeutics Slides: Study Result

Oct 3, 2025, 8:30 AM EDT - 11 months ago

Ovid Therapeutics Slides: Study Result

Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds

Oct 3, 2025, 7:05 AM EDT - 11 months ago

Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds

Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile

Oct 3, 2025, 7:00 AM EDT - 11 months ago

Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile

Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results

Aug 13, 2025, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results

Ovid Therapeutics Earnings release: Q2 2025

Aug 13, 2025, 3:00 AM EDT - 1 year ago

Ovid Therapeutics Earnings release: Q2 2025

Ovid Therapeutics Quarterly report: Q2 2025

Aug 13, 2025, 3:00 AM EDT - 1 year ago

Ovid Therapeutics Quarterly report: Q2 2025

Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference

Jul 23, 2025, 8:30 AM EDT - 1 year ago

Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference

Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties

Jun 25, 2025, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties

Ovid Therapeutics Transcript: Status Update

Jun 12, 2025, 9:30 AM EDT - 1 year ago

Ovid Therapeutics Transcript: Status Update

Ovid Therapeutics Slides: Status Update

Jun 12, 2025, 9:30 AM EDT - 1 year ago

Ovid Therapeutics Slides: Status Update

Ovid Therapeutics Slides: Corporate Presentation

Jun 12, 2025, 7:00 AM EDT - 1 year ago

Ovid Therapeutics Slides: Corporate Presentation

Ovid Therapeutics Proxy statement: Proxy Filing

May 22, 2025, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Proxy statement: Proxy Filing

Ovid Therapeutics Proxy statement: Proxy Filing

May 22, 2025, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Proxy statement: Proxy Filing

Ovid Therapeutics Slides: Corporate Presentation

May 16, 2025, 7:00 AM EDT - 1 year ago

Ovid Therapeutics Slides: Corporate Presentation

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results

May 13, 2025, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results

Ovid Therapeutics Earnings release: Q1 2025

May 13, 2025, 3:00 AM EDT - 1 year ago

Ovid Therapeutics Earnings release: Q1 2025

Ovid Therapeutics Quarterly report: Q1 2025

May 13, 2025, 3:00 AM EDT - 1 year ago

Ovid Therapeutics Quarterly report: Q1 2025

Ovid Therapeutics Proxy statement: Proxy Filing

May 2, 2025, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Proxy statement: Proxy Filing

Ovid Therapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 7, 2025, 8:45 AM EDT - 1 year ago

Ovid Therapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference

Ovid Therapeutics Slides: Corporate Presentation

Apr 5, 2025, 7:00 AM EDT - 1 year ago

Ovid Therapeutics Slides: Corporate Presentation

Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Ovid Therapeutics Slides: Corporate Presentation

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Slides: Corporate Presentation

Ovid Therapeutics Annual report: Q4 2024

Mar 11, 2025, 3:00 AM EDT - 1 year ago

Ovid Therapeutics Annual report: Q4 2024

Ovid Therapeutics Earnings release: Q4 2024

Mar 11, 2025, 3:00 AM EDT - 1 year ago

Ovid Therapeutics Earnings release: Q4 2024

Ovid Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 3:10 PM EST - 1 year ago

Ovid Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

Mar 3, 2025, 8:00 AM EST - 1 year ago

Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Feb 27, 2025, 8:00 AM EST - 1 year ago

Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Ovid Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 12, 2025, 4:00 PM EST - 1 year ago

Ovid Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 5, 2025, 8:00 AM EST - 1 year ago

Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Ovid Therapeutics Slides: Corporate Presentation

Jan 13, 2025, 7:00 AM EST - 1 year ago

Ovid Therapeutics Slides: Corporate Presentation

Ovid Therapeutics Slides: Corporate Presentation

Dec 27, 2024, 7:00 AM EST - 1 year ago

Ovid Therapeutics Slides: Corporate Presentation

Ovid Therapeutics Transcript: KCC2 Download Day 2024

Nov 13, 2024, 9:30 AM EST - 1 year ago

Ovid Therapeutics Transcript: KCC2 Download Day 2024

Ovid Therapeutics Slides: FY 2024

Nov 13, 2024, 9:30 AM EST - 1 year ago

Ovid Therapeutics Slides: FY 2024

Ovid Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

Ovid Therapeutics Quarterly report: Q3 2024

Ovid Therapeutics Earnings release: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

Ovid Therapeutics Earnings release: Q3 2024

Ovid Therapeutics Slides: Corporate Presentation

Nov 12, 2024, 7:00 AM EST - 1 year ago

Ovid Therapeutics Slides: Corporate Presentation

Ovid Therapeutics Slides: Corporate Presentation

Sep 26, 2024, 7:00 AM EDT - 2 years ago

Ovid Therapeutics Slides: Corporate Presentation

Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth

Sep 11, 2024, 8:00 AM EDT - 2 years ago

Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth

Ovid Therapeutics Slides: Corporate Presentation

Aug 15, 2024, 7:00 AM EDT - 2 years ago

Ovid Therapeutics Slides: Corporate Presentation

Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results

Aug 13, 2024, 8:00 AM EDT - 2 years ago

Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results

Ovid Therapeutics Quarterly report: Q2 2024

Aug 13, 2024, 3:00 AM EDT - 2 years ago

Ovid Therapeutics Quarterly report: Q2 2024

Ovid Therapeutics Earnings release: Q2 2024

Aug 13, 2024, 3:00 AM EDT - 2 years ago

Ovid Therapeutics Earnings release: Q2 2024

Ovid Therapeutics to Present at Upcoming August Investor Conferences

Jul 30, 2024, 8:00 AM EDT - 2 years ago

Ovid Therapeutics to Present at Upcoming August Investor Conferences

Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists

Jul 23, 2024, 8:00 AM EDT - 2 years ago

Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists

Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations

Jul 1, 2024, 8:00 AM EDT - 2 years ago

Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations

Ovid Therapeutics Slides: Corporate Presentation

Jun 17, 2024, 7:00 AM EDT - 2 years ago

Ovid Therapeutics Slides: Corporate Presentation

Ovid Therapeutics Reports on Takeda's Announcement of Phase 3 Topline Study Results for Soticlestat

Jun 17, 2024, 6:55 AM EDT - 2 years ago

Ovid Therapeutics Reports on Takeda's Announcement of Phase 3 Topline Study Results for Soticlestat

Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results

May 14, 2024, 8:00 AM EDT - 2 years ago

Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results

Ovid Therapeutics Slides: Corporate Presentation

May 14, 2024, 7:00 AM EDT - 2 years ago

Ovid Therapeutics Slides: Corporate Presentation

Ovid Therapeutics Quarterly report: Q1 2024

May 14, 2024, 3:00 AM EDT - 2 years ago

Ovid Therapeutics Quarterly report: Q1 2024

Ovid Therapeutics Earnings release: Q1 2024

May 14, 2024, 3:00 AM EDT - 2 years ago

Ovid Therapeutics Earnings release: Q1 2024

Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 13, 2024, 7:00 AM EDT - 2 years ago

Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Ovid Therapeutics Proxy statement: Proxy Filing

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Ovid Therapeutics Proxy statement: Proxy Filing

Ovid Therapeutics Proxy statement: Proxy Filing

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Ovid Therapeutics Proxy statement: Proxy Filing

Ovid Therapeutics Slides: Corporate Presentation

Apr 11, 2024, 7:00 AM EDT - 2 years ago

Ovid Therapeutics Slides: Corporate Presentation

Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Apr 4, 2024, 8:00 AM EDT - 2 years ago

Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results

Mar 8, 2024, 8:00 AM EST - 2 years ago

Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results

Ovid Therapeutics Annual report: Q4 2023

Mar 8, 2024, 2:00 AM EST - 2 years ago

Ovid Therapeutics Annual report: Q4 2023

Ovid Therapeutics Earnings release: Q4 2023

Mar 8, 2024, 2:00 AM EST - 2 years ago

Ovid Therapeutics Earnings release: Q4 2023

Ovid Therapeutics Slides: Corporate Presentation

Mar 7, 2024, 7:00 AM EST - 2 years ago

Ovid Therapeutics Slides: Corporate Presentation

Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

Feb 28, 2024, 8:00 AM EST - 2 years ago

Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

Dubbyy
Dubbyy Aug. 17 at 3:49 PM
$OVID Check out this article from TipRanks | Ovid Therapeutics: Buy Rating on Advancing OV329 Seizure Pipeline and Strong Cash Runway Through 2029 | https://tipranks.onelink.me/WJho/jpg3t97m
0 · Reply
LSOTradingDesk
LSOTradingDesk Aug. 15 at 9:16 PM
$OVID 👀
0 · Reply
Dubbyy
Dubbyy Aug. 14 at 2:59 PM
$OVID Check out this article from TipRanks | Reiterated Buy Rating on Ovid Therapeutics as Solid Pipeline Execution and Two-Year Cash Runway Support Unchanged $5 Price Target | https://tipranks.onelink.me/WJho/3eekpcxi
0 · Reply
Dubbyy
Dubbyy Aug. 13 at 8:10 PM
$OVID https://tipranks.onelink.me/WJho/8178p2wk
0 · Reply
lucabrix
lucabrix Aug. 13 at 8:10 PM
$OVID here we go again!
0 · Reply
focafoca99
focafoca99 Aug. 13 at 1:09 PM
$OVID issued a press release with Q2 2026 results and business updates.
0 · Reply
d_risk
d_risk Aug. 13 at 12:39 PM
$OVID - Ovid Therapeutics Inc - 10Q - Updated Risk Factors 🚨 Peer Alert: Risk-factor words are +136.6% above peer average (27,850 vs 11,769 across 655 peers). Ovid flags new risks from U.S. drug importation programs and expanding use of social media and generative AI/AI-based tools, which could trigger compliance issues, data/privacy leaks, IP loss, reputational damage and financial reporting control failures. #Biotechnology #Pharmaceuticals #DrugImportationRisks #AICompliance #DataPrivacy 🟢 Added 🟠 Removed https://d-risk.ai/OVID/10-Q/2026-08-13
0 · Reply
michaelhearn
michaelhearn Aug. 13 at 1:37 AM
$OVID 81% bought!
0 · Reply
lucabrix
lucabrix Aug. 4 at 7:46 PM
$OVID Reply!
0 · Reply
michaelhearn
michaelhearn Aug. 4 at 4:28 PM
$OVID waking up with rest of market. Raised target of $9
0 · Reply
Dubbyy
Dubbyy Aug. 3 at 1:32 PM
$OVID Check out this article from TipRanks | Ovid Therapeutics price target raised to $9 from $7 at Oppenheimer | https://tipranks.onelink.me/WJho/m5ay5qsn
0 · Reply
FORMER
FORMER Jul. 23 at 12:37 PM
$OVID On 3/6 Institutional Shares were 69,621,157 - 53.48% and today (7/23) Institutional Shares are now 110,246,843 - 59.07% 🤙
1 · Reply
FORMER
FORMER Jul. 23 at 12:36 PM
$OVID 🤙
0 · Reply
Jdstoner30
Jdstoner30 Jul. 22 at 1:05 AM
$OVID 👀
0 · Reply
michaelhearn
michaelhearn Jul. 17 at 2:18 PM
$OVID could turn bullish here with focus on energy and healthcare. Right at resistance here
0 · Reply
Jdstoner30
Jdstoner30 Jul. 17 at 2:50 AM
$OVID any news at all?
0 · Reply
focafoca99
focafoca99 Jul. 8 at 11:13 AM
$OVID added a new CFO, Charles Carter, effective July 6, with a $460K salary and bonus target.
0 · Reply
michaelhearn
michaelhearn Jul. 7 at 3:29 PM
$OVID so solid
0 · Reply
michaelhearn
michaelhearn Jun. 29 at 7:03 PM
$OVID above the 50 now
0 · Reply
Merlintrader
Merlintrader Jun. 25 at 3:03 PM
$UNCY Top priority! Russell 2026 Biotech Watchlist: , $GALT, $SPRB, $OVID and the Small-Cap Health Care Additions to Watch https://www.merlintrader.com/russell-2026-biotech-watchlist/
0 · Reply
michaelhearn
michaelhearn Jun. 24 at 6:23 PM
$OVID short covering above 2.60? Maybe sooner
0 · Reply
michaelhearn
michaelhearn Jun. 24 at 1:49 PM
$OVID this should start moving up
0 · Reply